Benfotiamine is a form of thiamin (vitamin B1), an essential nutrient that is one of the eight water-soluble vitamins in the B-complex family. It plays a critical role in ensuring a healthy nervous system and enhancing the cardiovascular functioning of the body. Thiamin is an effective inhibitor of advanced glycation end-products (AGEs). It also activates an enzyme which supports the body’s ability to properly disperse sugar throughout the body.
Some of the symptoms of thiamine deficiency are poor appetite, digestive problems, degeneration of parts of the brain, nerve damage, vascular resistance, and dilation of the heart, among others. While thiamin is poorly absorbed by the body, benfotiamine helps maintain thiamin’s AGE-inhibiting benefits and allows it to pass directly into cells.
AOR’s Benfotiamine highly bioavailable formula helps support nerve function, promotes healthy aging, and prevents thiamine deficiency.
Benfotiamine is a naturally-occurring form of thiamin (vitamin B1). Benfotiamine’s superior ability to penetrate cell membranes increases its bioavailability over conventional thiamin supplements. This allows for the use of benfotiamine to promote all of the benefits of vitamin B1.*
AOR™ guarantees that all ingredients have been declared on the label. Made without wheat, gluten, corn, nuts, peanuts, sesame seeds, sulfites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.
Take one capsule one to four times a day with food, or as directed by a health care practitioner.
Do not use if you are pregnant or breastfeeding. Consult a health care provider if you have a medical condition, or are taking any medication. Persons with thiamin hypersensitivity should not take this product. Keep out of reach of children.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Other Ingredients: microcrystalline cellulose, sodium stearyl fumarate.
Capsule: hypromellose and purified water.
Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. “Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.” Nat Med. 2003 Mar; 9(3): 294-9.
Koltai MZ. “Prevention of cardiac autonomic neuropathy in dogs with Benfotiamine.” In Gries FA, Federlin K. “Benfotiamine in the Therapy of Polyneuropathy.” New York: Georg Thieme Verlag, 1998; 45-9.
Lin J, Alt A, Liersch J, Bretzel RG, Brownlee MA, Hammes HP. “Benfotiamine inhibits intracellular formation of advanced glycation endproducts in vivo.” Diabetes. 2000 May; 49(Suppl1): A143 (P583).
Loew D. “Pharmacokinetics of thiamine derivatives especially of Benfotiamine.” Int J Clin Pharmacol Ther. 1996 Feb; 34(2): 47-50.
Stracke H, Lindemann A, Federlin K. “A Benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.” Exp Clin Endocrinol Diabetes 1996; 104(4): 311-6.
Winkler G, Pal B, Nagybeganyi E, Ory I, Porochnavec M, Kempler P. “Effectiveness of different Benfotiamine dosage regimens in the treatment of painful diabetic neuropathy.” Arzneimittelforschung. 1999 Mar; 49(3): 220-4.